Adicet Bio, Inc. (ACET)
 NASDAQ: ACET · Real-Time Price · USD
 0.7794
 +0.0289 (3.85%)
  At close: Oct 30, 2025, 4:00 PM EDT
0.7564
 -0.0230 (-2.95%)
  Pre-market: Oct 31, 2025, 4:11 AM EDT
Adicet Bio Employees
Adicet Bio had 152 employees as of December 31, 2024. The number of employees increased by 9 or 6.29% compared to the previous year.
Employees 
 152
Change (1Y) 
 9
Growth (1Y) 
 6.29%
Revenue / Employee 
 n/a
Profits / Employee 
 -$780,500
Market Cap 
126.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 152 | 9 | 6.29% | 
| Dec 31, 2023 | 143 | 11 | 8.33% | 
| Dec 31, 2022 | 132 | 46 | 53.49% | 
| Dec 31, 2021 | 86 | 4 | 4.88% | 
| Dec 31, 2020 | 82 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
ACET News
- 2 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 14 days ago - Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) - Business Wire
- 23 days ago - Adicet Bio, Inc. - Special Call - Seeking Alpha
- 23 days ago - Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 - Benzinga
- 23 days ago - Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - Business Wire
- 23 days ago - Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - Business Wire
- 4 weeks ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire